Lab Notes Newsletter
Welcome to the March edition of our newsletter!
For 40 years, we’ve helped scientists harness the full potential of biology with next-generation technology. Here we share the latest in automated, end-to-end solutions that span research disciplines to advance scientific discovery and improve the quality of human life worldwide.
A New Collaboration Finds a Match Between Liver-Derived Organoids and Automated Screening Technologies
Following our announced collaboration with Cincinnati Children's, we had some insightful questions come through from LabX Media Group Technology Editor Damon Anderson, PhD, around advanced organoid screening platforms and their promise to advance drug development and disease research:
The high rate of drug failure during development can often be attributed to a lack of translational efficacy from the pre-clinical phase to the clinic.
Organoids show great promise in disease modeling and drug screening since they better resemble tissue structure and functionality, but organoids can also be difficult to work with. To alleviate some of the issues that come with 3D biology, we developed a fully automated workflow for several commonly used organoid protocols.
Read the scientific poster where we feature a protocol that includes the culture of 3D organoids in matrix domes using the new CellXpress.ai Automated Cell Culture System to increase throughput and reproducibility.
Organoid technology holds significant promise in transforming drug discovery.
The combination of large-scale organoid production with automation-based screening workflows will overcome some of the current barriers to organoid use. Read the scientific poster to learn how we used assay-ready organoids to generate image-based readouts, along with morphological profiling, to help understand complex phenotypes associated with patient-derived organoids (PDOs).
Our results demonstrate the utility of PDOs in high-throughput drug discovery applications using automation with high-content imaging.
Cell Viability Assays: Drug Response Gateway
Dive into the heart of your research with our latest infographic on Cell Viability Assays! Learn more about the techniques and tools that are transforming how scientists measure and interpret cell health.
What you'll learn about:
Discover Breakthrough Insights: Assessing Drug Effects in Patient-Derived Colorectal Cancer Organoids
Our latest poster showcases a groundbreaking approach to rapidly identify effective drug candidates using automated analyses of organoid size, morphology, and viability. By combining label-free imaging with an automated microplate reader-based ATP assay, researchers can quantitatively analyze drug responses and accelerate the identification of potential drugs with measurable effects on organoids.
Recommended by LinkedIn
Optimize stem cell research with our technology for precise monoclonality and enhanced bioprocess efficiency.
Set new benchmarks and attain 99% verification for unmatched purity in hiPSCs research. Our newest application note unveils a pioneering solution tailored to tackle the complexities of hiPSC cloning and screening, promising to redefine your research outcomes.
In the rapidly evolving field of biotechnology, the path to innovation is paved with challenges, especially when it comes to achieving regulatory milestones such as Investigational New Drug (IND) filings.
Our latest application note, "Unlock IND Filing Success with DispenCell: Achieving 98.4% Clonality," offers an in-depth exploration of how DispenCell, combined with fluorescence imaging, is designed to meet the stringent regulatory requirements for commercial manufacturing, ensuring the highest safety and quality of your biopharmaceutical products.
Revolutionize your Cardiotoxicity Testing
Traditional cardiotoxicity testing methods can take weeks or even months to complete, slowing down your research and drug development timelines. If you no longer want to rely on traditional, time-consuming, and costly methods for cardiotoxicity testing, we are here to help. Our state-of-the-art technology within the FLIPR Penta allows for rapid and accurate cardiotoxicity assessment, enabling you to identify potential issues earlier and make informed decisions faster.
With the FLIPR Penta, you can:
Don't let traditional cardiotoxicity testing methods hold you back 👇
EVENTS
April 05-10, 2024 | San Diego, CA
April 09-12, 2024 | Munich, DE
April 14-17, 2024 | Tampa, FL
May 06-09, 2024 | San Jose, CA